^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Non Small Cell Lung Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A single-arm, prospective, open-label clinical study of carilizumab combined with apatinib in the treatment of non-small cell lung cancer with TP53 gene mutation

    Excerpt:
    ...Patients with EGFR gene mutation or ALK gene rearrangement, who have received standard treatment to obtain disease progress and have TP53 gene mutation detected; 5. ...
    Trial ID:
    ChiCTR2000031978
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Transl Lung Cancer Res
    Title:

    Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

    Excerpt:
    Previously treated patients with advanced EGFR+/ALK+ NSCLC were enrolled and given camrelizumab 200 mg intravenously every 2 weeks plus apatinib at the recommended dose of 250 mg orally once daily…. The confirmed ORR was 18.6% (95% CI: 8.4–33.4%) and the clinical benefit response rate was 27.9% (95% CI: 15.3–43.7%).
    DOI:
    10.21037/tlcr-22-22
    Trial ID:
    NCT03083041